Low-profile stand offers 'quick-connect' mounting system

Civco Medical Instruments offers the Micro-Touch LP (low-profile) stand,created to satisfy the special requirements for performing prostate brachytherapyprocedures on cystoscopy tables with a fixed overhead x-ray or fluoroscopygantry.

Related Videos

Experts assess pre-operative factors linked with buccal mucosa graft failure

Interim Results from ADVANCED 2

Integrating ctDNA in NMIBC: Promise and practical challenges

TARA-002 mechanism of action

Robert Jansen, MD, discusses evaluation of candidates for testosterone therapy

Ashley Winter, MD, discusses testosterone therapy for women

Vikram Narayan, MD, on embracing thoughtful tech adoption

Eating disorders and pelvic health: What clinicians need to know

Adherence of Various ADT Options

Initiating ADT: Factors to Consider

Related Content

Advertisement

August 1st 2025

Biopsy grade alone may underestimate risk in GG1 prostate cancer

Hannah Clarke

Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.

August 1st 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 1st 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

August 1st 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 1st 2025

Trial launches of ABO-101 for primary hyperoxaluria type 1

Hannah Clarke

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

August 1st 2025

Enzalutamide shows improved relative efficacy over darolutamide in mHSPC

Hannah Clarke

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

Related Content

Advertisement

August 1st 2025

Biopsy grade alone may underestimate risk in GG1 prostate cancer

Hannah Clarke

Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.

August 1st 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 1st 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

August 1st 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 1st 2025

Trial launches of ABO-101 for primary hyperoxaluria type 1

Hannah Clarke

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

August 1st 2025

Enzalutamide shows improved relative efficacy over darolutamide in mHSPC

Hannah Clarke

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.